Drug Combination Details

General Information of the Combination (ID: C73107)
Name Vincristine   NP Info  + Rituximab   Drug Info 
Structure +
Disease
B-cell lymphoma [ICD-11: 2A86]
Phase 3 [1]
Mantle cell lymphoma [ICD-11: 2A85]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Biological
                    Regulation		 Increase Tumor cell death
                    In-vitro Model Ramos CVCL_0597 Burkitt lymphoma Homo sapiens
                    Experimental
                    Result(s)		 Rituximab synergizes with vincristine in the killing of Ramos Burkitt's lymphoma B cell line.
References
Reference 1 ClinicalTrials.gov (NCT01478542) Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution.
Reference 2 Rituximab synergizes with hydroxyurea or vincristine in the killing of Ramos Burkitt's lymphoma B cell line. Cancer Biother Radiopharm. 2014 Mar;29(2):87-90.
 Download Picture         KEGG Link